3.5-Dimethyl-4-vinyl-pyridin | 90609-56-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 3.5-Dimethyl-4-vinyl-pyridin
• 英文别名: 3,5-dimethyl-4-vinyl-pyridine；3,5-Dimethyl-4-vinylpyridine；4-ethenyl-3,5-dimethylpyridine
• CAS: 90609-56-6
• 化学式: C₉H₁₁N
• 分子量: 133.193
• InChiKey: MDMMYFSXDYTJAH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• [EN] HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF FIBROTIC DISEASE<br/>[FR] DÉRIVÉS HÉTÉROCYCLIQUES, COMPOSITIONS PHARMACEUTIQUES ET LEUR UTILISATION DANS LE TRAITEMENT, LE SOULAGEMENT OU LA PRÉVENTION DE MALADIE FIBROTIQUE
  申请人：TOLREMO THERAPEUTICS AG

  公开号：WO2021260110A1

  公开（公告）日：2021-12-30

  The present invention relates to a compound of formula (I), optionally in the form of a pharmaceutically acceptable salt, solvate, cocrystal, tautomer, racemate, enantiomer, or diastereomer or mixture thereof and to pharmaceutical compositions comprising a compound of formula (I), as well as to the use of a compound of formula (I), or a pharmaceutically acceptable salt, solvate, cocrystal, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, in the treatment of fibrotic diseases, preferably idiopathic pulmonary fibrosis (IPF) or non-alcoholic steatohepatitis (NASH). Further aspects of the present invention include combination therapies in which a compound of formula (I), optionally in the form of a pharmaceutically acceptable salt, solvate, cocrystal, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, is used in combination with a known anti-fibrotic or anti-inflammatory agents for fibrotic diseases.

  本发明涉及一种化合物，其化学式为(I)，可选地以药学上可接受的盐、溶剂合物、共晶体、互变异构体、外消旋体、对映体或二对映体形式存在，以及包含化合物(I)的药物组合物，以及使用化合物(I)或药学上可接受的盐、溶剂合物、共晶体、互变异构体、外消旋体、对映体或二对映体或其混合物治疗纤维化疾病，优选为特发性肺纤维化（IPF）或非酒精性脂肪性肝炎（NASH）。本发明的其他方面包括组合疗法，其中化合物(I)，可选地以药学上可接受的盐、溶剂合物、共晶体、互变异构体、外消旋体、对映体或二对映体形式存在，与已知的抗纤维化或抗炎症药物一起用于治疗纤维化疾病。
• Cell-culturing substrate, cell-culturing substrate unit bioreactor and extracorporeal circulation type therapeutic apparatus
  申请人：TERUMO KABUSHIKI KAISHA

  公开号：EP0402272B1

  公开（公告）日：1995-10-04
• US5658706A
  申请人：——

  公开号：US5658706A

  公开（公告）日：1997-08-19
• [EN] COMPOUNDS AS ROR?T MODULATORS AND USES THEREOF<br/>[FR] COMPOSÉS EN TANT QUE MODULATEURS DE ROR?T ET LEURS UTILISATIONS
  申请人：UNIV NEW YORK

  公开号：WO2011112264A1

  公开（公告）日：2011-09-15

  Heterocyclic compounds, and pharmaceutical compositions thereof, are disclosed as RORyt modulators that have a formula represented by the following: and wherein n l, n2, R1, R2, R3, and R4 are as described herein. These compounds may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammatory conditions, autoimmune disorders, cancer, and graft-versus-host disease.